Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
SINOPHARM's Subsidiary Sinopharm Accord Envisions Max. 90% Surge in Last Yr's NP
Recommend 2 Positive 4 Negative 0 |
||||
|
||||
|
Sinopharm Accord (000028.SZ), a subsidiary of SINOPHARM (01099.HK), anticipates a YoY growth of around 64.20-89.11% in the 2025 net profit attributable to shareholders of the listed company to around RMB1.055-1.215 billion. During the period, Sinopharm Accord's net profit excluding non-recurring gains and losses is expected to have risen by around 71.38-98.91% YoY to around RMB996 million to RMB1.156 billion, while basic earnings per share will have reached around RMB1.9-2.18, compared to RMB1.15 in the previous year. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
